HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,105.00
-15.00 (-0.71%)
Sep 1, 2026, 3:30 PM KST

HLB Therapeutics Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
64,44769,56154,93252,59142,40343,586
Other Revenue
-0-0--0-0-
64,44769,56154,93252,59142,40343,586
Revenue Growth
5.25%26.63%4.45%24.03%-2.72%1.53%
Cost of Revenue
60,42659,52944,95345,40633,68238,579
Gross Profit
4,02110,0329,9797,1848,7215,007
Selling, General & Admin
10,77311,96616,19215,23615,67315,641
Amortization of Goodwill & Intangibles
16.5933.62114.2648.320.7999.66
Other Operating Expenses
237.99249.32301.46183273.11240.04
Operating Expenses
13,32313,61417,60316,05316,22816,094
Operating Income
-9,302-3,582-7,624-8,869-7,507-11,087
Interest Expense
-1,682-1,916-1,964-1,112-5,146-1,160
Interest & Investment Income
389.64639.72984.551,1661,23096.09
Earnings From Equity Investments
-9,901-7,594-433.03802.4--
Currency Exchange Gain (Loss)
449.25189.494,48294.65327.0397.78
Other Non Operating Income (Expenses)
95.47-163.031,363-3,430-1,33415.88
EBT Excluding Unusual Items
-19,951-12,427-3,193-11,347-12,430-12,038
Gain (Loss) on Sale of Investments
1,9263,016-11,6787,7541,879-359.48
Gain (Loss) on Sale of Assets
-65.17234.25-17.694.04-598.18-14.8
Asset Writedown
-22.72-22.72-8,037--424.08-4,632
Other Unusual Items
-1,918-1,887-624.11--720.83
Pretax Income
-20,030-11,086-22,926-2,965-11,573-17,764
Income Tax Expense
-1,458-1,418----
Earnings From Continuing Operations
-18,573-9,668-22,926-2,965-11,573-17,764
Earnings From Discontinued Operations
---534.08-113.98-530.86-
Net Income to Company
-18,573-9,668-23,460-3,079-12,104-17,764
Minority Interest in Earnings
550.69441.2666.96777.16750.45567.08
Net Income
-18,022-9,227-22,793-2,302-11,354-17,197
Net Income to Common
-18,022-9,227-22,793-2,302-11,354-17,197
Net Income Growth
------
Shares Outstanding (Basic)
888884827164
Shares Outstanding (Diluted)
888884827164
Shares Change
3.32%4.35%3.23%14.46%10.86%7.26%
EPS (Basic)
-204.45-104.74-270.00-28.15-158.92-266.85
EPS (Diluted)
-204.45-104.74-270.00-28.15-158.92-266.85
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-4,728-9,463650.793,025-12,204-12,091
Free Cash Flow Per Share
-53.64-107.427.7136.99-170.82-187.61
Gross Margin
6.24%14.42%18.17%13.66%20.57%11.49%
Operating Margin
-14.43%-5.15%-13.88%-16.86%-17.70%-25.44%
Profit Margin
-27.96%-13.26%-41.49%-4.38%-26.78%-39.45%
Free Cash Flow Margin
-7.34%-13.60%1.19%5.75%-28.78%-27.74%
EBITDA
-7,0451,040467.85-389.34-5,841-9,386
EBITDA Margin
-10.93%1.50%0.85%-0.74%-13.78%-21.54%
D&A For EBITDA
2,2574,6228,0928,4791,6661,701
EBIT
-9,302-3,582-7,624-8,869-7,507-11,087
EBIT Margin
-14.43%-5.15%-13.88%-16.86%-17.70%-25.44%
Advertising Expenses
--0.69-0.217.07